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Abstract
Background: Esophageal Crohn’s disease is reported as a rare manifestation, although its prevalence may be
underestimated because upper endoscopies are not routinely performed in asymptomatic adults. Tofacitinib, an
oral janus kinase inhibitor, is a new biologic that has shown promise in the treatment of ulcerative colitis and may
be effective in the treatment of Crohn’s disease according to phase 2 trials. We report the first case of esophageal
Crohn’s disease successfully treated with tofacitinib in a patient with worsening symptoms despite maintenance
therapy with a tumor necrosis factor-α inhibitor.
Case presentation: A 67-year-old Caucasian woman presented with new dysphagia and had findings of
esophageal Crohn’s disease on endoscopy. The dosage of her current biologic therapy—adalimumab—was
increased in frequency, without improvement. Our patient was started on tofacitinib and demonstrated an
improvement in symptoms, with a repeat endoscopy showing resolution of the previous lesions.
Conclusion: Esophageal Crohn’s disease is likely underdiagnosed but is an important consideration in a patient
with new symptoms of dysphagia and known Crohn’s disease. Tofacitinib, while a novel agent, could have a
role in the treatment of esophageal Crohn’s disease that does not improve with intensification of the current
biologic therapy. It provides a different mechanism in patients who become refractory to maintenance
therapy.
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Background
Esophageal manifestations of Crohn’s disease (CD) in-
clude erosion, ulceration, stricture, and fistula formation.
Patients can present with odynophagia and/or dysphagia,
but more serious manifestations including bronchoeso-
phageal fistula have been reported [1]. Involvement of
the esophagus in CD is rare and it is the least commonly
affected segment in CD [1]. Additionally, the lack of
standard upper endoscopy in asymptomatic adult
patients with CD could also contribute to its low inci-
dence [2]. Therefore, the prevalence of esophageal
Crohn’s disease could be underestimated; it is currently
reported as being 1–6.8 % in the literature [1–4]. In
contrast, there is a higher incidence of esophageal CD
reported in the pediatric population because screening
upper endoscopy is performed at the time of diagnosis
given the high degree of proximal active disease,
although patients are typically asymptomatic [2]. How-
ever, new studies suggest that upper gastrointestinal
involvement is seen equally in the adult and pediatric
populations [5]. There is a lack of consensus in the
definition of involvement and, until recently, on treat-
ment [4, 5]. However, recent guidelines suggest treat-
ment with immunomodulators, and tumor necrosis
factor-α (TNF-α) inhibitors if the disease is more refrac-
tory; both options have been described in several case
series with success [2, 6, 7]. We report the first case of
esophageal CD successfully treated with tofacitinib, an
oral janus kinase (JAK) inhibitor, in a patient with
known CD. To the best of our knowledge, this is the first
reported case of its use in esophageal CD. We also
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review the presentation, diagnosis, and treatment of
esophageal CD.
Case presentation
A 67-year-old Caucasian woman with a history of small
and large bowel CD presented with new dysphagia. She
was diagnosed with CD at age 30. Her disease had been
complicated by fistula formation and multiple small
bowel resections, as well as small intestinal bacterial
overgrowth, chronic diarrhea, and osteoporosis. At the
time of presentation, she had been on adalimumab (40
mg every other week) and mesalamine for 2 years. Previ-
ous medications included 6-mercaptopurine, azathioprine,
methotrexate, infliximab, prednisone, and budesonide.
She was not on a proton pump inhibitor at the time. Her
vital signs were all within normal limits and her physical
examination was unremarkable.
An upper endoscopy was performed and revealed
deep linear ulcerations throughout the majority of
her esophagus (Fig. 1) with a normal stomach and
duodenum. Esophageal biopsies showed lymphocytic
esophagitis characterized by dense lymphoplasmacytic
infiltrates within the mucosa and lamina propria and an
ill-formed granulomatous reaction consistent with an
esophageal manifestation of CD (Fig. 2). Results from
staining for acid-fast organisms with acid-fast bacillus
(AFB) stain were negative and no viral cytopathic effects
or intra-cellular inclusions were found. Our patient also
had negative results in an interferon-gamma (IFN-γ) release
assay, no remarkable findings on a chest X-ray, and com-
puted tomography enterography that was negative for any
intraluminal masses.
Our patient was subsequently started on a budesonide
suspension but had an inadequate clinical response after
5 months. Thus, adalimumab was increased to 40 mg
every week. A repeat endoscopy showed mid-esophageal
ulcerations that were biopsied. Examination of the speci-
mens demonstrated inflamed granulation tissue and in-
flammatory exudate. Immunohistochemical stains of the
biopsy specimens were negative for herpes simplex virus
and cytomegalovirus. At this point, omeprazole 40 mg
once daily was started, but her symptoms persisted des-
pite intensified TNF-α inhibitor therapy and concurrent
proton pump inhibitor use. Adalimumab was thus
stopped. Tofacitinib 5 mg twice daily was started after
consideration of both ustekinumab and a drug trial in-
volving an interleukin (IL) 6 inhibitor. Ustekinumab use
was precluded by insurance and cost. Vedolizumab had
not yet been approved for clinical use.
Six months later our patient was seen in a follow-up
appointment and had no esophageal symptoms. A repeat
endoscopy with biopsies was performed 7 months after
she started taking tofacitinib. This study demonstrated
esophageal scarring and nonspecific chronic inflamma-
tion in her distal esophagus, but showed complete reso-
lution of her previous ulcerative disease (Fig. 3). Biopsies
demonstrated that her mucosa showed no significant
granulomatous changes as were previously found (Fig. 4).
A repeat endoscopy 2 years after tofacitinib initiation
was unremarkable and she did not experience any ad-
verse events.
Discussion
There are several presentations of esophageal CD that
the reader should be made aware of. These include
dysphagia or odynophagia as seen in our patient due to
deep ulcers, strictures with or without fistula in an older
patient, or asymptomatic in patients with normal endos-
copy results but abnormal histology [1–3]. The latter is
seen in pediatric patients, who have a high prevalence of
esophageal CD when surveyed with upper endoscopy
[1]. Patients may also present with chest pain, heartburn,
nausea, and vomiting [8]. Almost all cases are seen with
CD affecting other segments of the gastrointestinal tract,
although isolated esophageal involvement has also been
reported [3, 9]. Diagnosis is aided by endoscopy but re-
quires an integration of clinical, endoscopic, histological,
and radiographic data [2, 3]. Findings on endoscopy
Fig. 1 Endoscopic findings of longitudinal, serpiginous ulcerations along the entirety of the esophagus consistent with an esophageal manifestation
of Crohn’s disease. Our patient was on adalimumab and mesalamine at the time
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include aphthous ulcers, superficial erosions, friability,
and nodular thickening [3]. The importance of biopsies
cannot be underscored enough given the broad differ-
ential diagnosis, although histological findings may not
be specific for CD, making the diagnosis difficult [2].
The transmural nature of CD is also a factor, which
cannot be assessed with superficial biopsies taken dur-
ing endoscopy. Histological findings include chronic,
non-specific inflammation with or without granulomas,
although these are rarely observed [5, 8, 10]. Granu-
lomas are seen in only 20–30 % of grossly abnormal
biopsies but are considered pathognomonic for CD
diagnosis [4].
While our patient had histological evidence of esophageal
CD, the differential diagnosis would also include reflux
esophagitis, pill esophagitis, viral esophagitis (cytomegalo-
virus and herpes simplex virus), monilial esophagitis,
granulomatous diseases such as sarcoidosis, tuberculosis,
necrotizing vasculitis, Behçet’s syndrome, disseminated
fungal infection, epidermolysis bullosa acquisita, and
carcinoma [1, 3, 8–10]. Achalasia should also be ruled
out with motility testing if symptoms are classic; how-
ever, abnormal motility has been described even in
patients with inactive CD for unclear reasons and
esophageal CD can present like pseudoachalasia [10].
Tuberculosis can be ruled out when biopsies are
stained for acid-fast organisms.
CD is known to affect any portion of the gastrointestinal
tract; however, the distal third of the esophagus alone is
the most common esophageal manifestation (80 %) [3].
Radiographic studies can show ulcers or strictures, but
can be normal in up to 50 % of patients with esophageal
CD [3]. Other findings include stricture and fistula. The
management of these complications entails endoscopic
dilation and esophagectomy. For fistula, closure has been
described with polymer sealants and infliximab, although
many require surgical repair [4]. Given that esophageal
CD is a high risk feature indicative of aggressive disease
activity, endoscopy should be considered in all patients
with CD with upper gastrointestinal symptoms to avoid
complications [2, 4].
Medical management is first line when a diagnosis of
esophageal CD is made. Currently, the European Crohn’s
and Colitis Organisation (ECCO) consensus guidelines
suggest esophageal CD should be treated with a proton
pump inhibitor, in addition to steroids and thiopurines
or methotrexate [11]. Treatment options have histo-
rically included 5-aminosalicylic acid preparations, al-
though it is unclear how effective they are because their
metabolites are not active in the proximal gastrointes-
tinal tract [8, 9]. Corticosteroids, systemic as well as
topical, such as swallowed aerosolized budesonide, have
also been described [3, 5, 9]. Immunomodulators includ-
ing azathioprine and 6-mercaptopurine have also been
Fig. 2 Esophageal biopsies from an initial endoscopy that show granulomatous changes on low (left) and high (right) magnification
Fig. 3 Repeat endoscopy shows healed esophageal mucosa following initiation of tofacitinib
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described; they are steroid-sparing and treat more distal
disease if present [5, 9]. There is one case report on the
successful use of thalidomide [7]. There are been several
case reports commenting on the use of biologics for
esophageal CD in recent years as these drugs have
become a cornerstone of inflammatory bowel disease
treatment. ECCO guidelines recommend a lower thresh-
old for starting TNF-α inhibitors for esophageal involve-
ment than for disease elsewhere owing to the poor
prognosis associated with this site [11]. Use of infliximab,
adalimumab, and ustekinumab has been associated with
rapid improvement on repeat endoscopy [2, 6, 12, 13].
These findings imply that repeat endoscopy should be
performed in patients with persistent symptoms to rule
out other causes or to confirm persistent disease activity.
Optimization of medical therapy is important to minimize
complications such as stricture and fistula formation.
Patients with persistent dysphagia due to strictures may
require dilatation, stent placement, or ultimately surgery
for management [3]. Patients are usually also started on a
proton pump inhibitor, which can help symptoms but
whose role in mucosal healing is unclear.
Tofacitinib, a selective oral inhibitor of JAK 1 through
3, is currently approved for use in patients with rheuma-
toid arthritis. Inhibition of JAK1 and JAK3 blocks signal-
ing for many cytokines, including IL-2, IL-4, IL-6, IL-7,
IL-9, IL-15, IL-21, and IFN-γ, which are involved in
immune activation and signaling [14, 15]. Phase 3 trials
for the treatment of moderate to severe active ulcerative
colitis are currently underway after a positive result from
a phase 2 trial that showed significant improvement in
primary and secondary endpoints with 15 mg twice daily
dosing [14–16]. A separate report from this study
demonstrated statistically significant patient reported
outcomes when compared to placebo, which correlated
with other objective assessments of drug efficacy [15]. A
phase 2 trial of tofacitinib for moderate to severe CD
published in 2014 was unable to demonstrate an im-
provement in clinical response or clinical remission
when compared to placebo, although they reported it
was unclear whether this was a true negative result or
related to a high placebo response rate [14, 17]. De-
creases in objective markers of inflammation including
C-reactive protein and fecal calprotectin suggest that
tofacitinib did have biologic activity in this study in
patients with CD [14].
One recent retrospective case series, the largest in
esophageal CD, reported that categorization of treatment
should be based on disease behavior—inflammatory,
stricturing, and fistulizing [2]. It is unclear from the
literature if disease activity in the esophagus mirrors
more distal disease activity or phenotype, although a
similarity has been noted on endoscopy [4]. Interest-
ingly, eight patients were on TNF-α inhibitors at the
time of diagnosis, and had a clinical response with dose
adjustment, adding another agent, or switching TNF-α
inhibitors [2]. Our patient had already had unsuccessful
trials of other medications for distal disease, thus pre-
cluding their use when her esophageal CD was diag-
nosed. Switching to another biologic has been described
and should be of consideration if there is no improve-
ment with intensification of the current therapy.
Conclusions
Esophageal CD may be a difficult diagnosis to obtain and
requires a crossroads between clinical, endoscopic, histo-
logical, and radiographic data. This case highlights the use
of tofacitinib as an alternative therapy for patients with
esophageal CD, and should be a consideration especially
in patients who do not benefit from TNF-α inhibitor use.
This case also highlights the ability of patients to de-
velop esophageal CD during TNF-α inhibitor therapy, a
phenomenon previously described in the literature [5].
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